5 Firms Aid As Jazz Pays $7.2B For Rare Disease Drugmaker
Jazz Pharmaceuticals PLC has agreed to pay $7.2 billion to pick up GW Pharmaceuticals PLC, which develops cannabinoid-based treatments for rare diseases, the companies said Wednesday, in a deal cooked up...To view the full article, register now.
Already a subscriber? Click here to view full article